GB201219602D0 - Recombinant clostridium botulinum neurotoxins - Google Patents

Recombinant clostridium botulinum neurotoxins

Info

Publication number
GB201219602D0
GB201219602D0 GB201219602A GB201219602A GB201219602D0 GB 201219602 D0 GB201219602 D0 GB 201219602D0 GB 201219602 A GB201219602 A GB 201219602A GB 201219602 A GB201219602 A GB 201219602A GB 201219602 D0 GB201219602 D0 GB 201219602D0
Authority
GB
United Kingdom
Prior art keywords
clostridium botulinum
botulinum neurotoxins
recombinant clostridium
recombinant
neurotoxins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB201219602A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntaxin Ltd
Ipsen Biopharm Ltd
Original Assignee
Syntaxin Ltd
Ipsen Biopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntaxin Ltd, Ipsen Biopharm Ltd filed Critical Syntaxin Ltd
Priority to GB201219602A priority Critical patent/GB201219602D0/en
Publication of GB201219602D0 publication Critical patent/GB201219602D0/en
Priority to PL13811605T priority patent/PL2914282T3/pl
Priority to TW102139558A priority patent/TWI626307B/zh
Priority to DK13811605.8T priority patent/DK2914282T3/en
Priority to TW107110108A priority patent/TWI673361B/zh
Priority to PL17201198T priority patent/PL3326644T3/pl
Priority to HUE13811605A priority patent/HUE036764T2/hu
Priority to KR1020157010099A priority patent/KR102188539B1/ko
Priority to EP13811605.8A priority patent/EP2914282B1/en
Priority to EP17201198.3A priority patent/EP3326644B1/en
Priority to NO13811605A priority patent/NO2914282T3/no
Priority to TW108125708A priority patent/TW202012622A/zh
Priority to PCT/GB2013/052845 priority patent/WO2014068317A1/en
Priority to UAA201502159A priority patent/UA118837C2/uk
Priority to SG10201701140WA priority patent/SG10201701140WA/en
Priority to AU2013340610A priority patent/AU2013340610B2/en
Priority to ARP130103981A priority patent/AR093309A1/es
Priority to EA201590794A priority patent/EA201590794A8/ru
Priority to KR1020207026658A priority patent/KR102264478B1/ko
Priority to SG11201502372SA priority patent/SG11201502372SA/en
Priority to PT138116058T priority patent/PT2914282T/pt
Priority to CN201380047542.8A priority patent/CN104755098A/zh
Priority to EP20153122.5A priority patent/EP3673914B1/en
Priority to BR112015005384A priority patent/BR112015005384A2/pt
Priority to NZ705575A priority patent/NZ705575A/en
Priority to DK17201198.3T priority patent/DK3326644T3/da
Priority to HUE17201198A priority patent/HUE048802T2/hu
Priority to CA2885519A priority patent/CA2885519A1/en
Priority to ES13811605.8T priority patent/ES2662402T3/es
Priority to JP2015540207A priority patent/JP2015534814A/ja
Priority to ES17201198T priority patent/ES2788199T3/es
Priority to CN201910795176.3A priority patent/CN110499321A/zh
Priority to HK15109067.2A priority patent/HK1208359B/en
Priority to PT172011983T priority patent/PT3326644T/pt
Priority to MX2015005156A priority patent/MX367080B/es
Priority to IN436MUN2015 priority patent/IN2015MN00436A/en
Priority to US14/427,234 priority patent/US10030238B2/en
Priority to ZA2015/01449A priority patent/ZA201501449B/en
Priority to IL237623A priority patent/IL237623B/en
Priority to MX2019009222A priority patent/MX2019009222A/es
Priority to AU2018203556A priority patent/AU2018203556B2/en
Priority to JP2018230980A priority patent/JP2019068823A/ja
Priority to ARP190103867A priority patent/AR117738A2/es
Priority to JP2020017612A priority patent/JP2020078321A/ja
Priority to AU2020244481A priority patent/AU2020244481A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GB201219602A 2012-10-31 2012-10-31 Recombinant clostridium botulinum neurotoxins Ceased GB201219602D0 (en)

Priority Applications (45)

Application Number Priority Date Filing Date Title
GB201219602A GB201219602D0 (en) 2012-10-31 2012-10-31 Recombinant clostridium botulinum neurotoxins
US14/427,234 US10030238B2 (en) 2012-10-31 2013-10-31 Recombinant clostridium botulinum neurotoxins
EP20153122.5A EP3673914B1 (en) 2012-10-31 2013-10-31 Solid compositions comprising recombinant clostridium botulinum neurotoxins
BR112015005384A BR112015005384A2 (pt) 2012-10-31 2013-10-31 neurotoxinas clostridium botuliem recombinantes
DK13811605.8T DK2914282T3 (en) 2012-10-31 2013-10-31 Recombinant clostridium botulinum neurotoxins
TW107110108A TWI673361B (zh) 2012-10-31 2013-10-31 重組肉毒桿菌（Ｃｌｏｓｔｒｉｄｉｕｍ ｂｏｔｕｌｉｎｕｍ）神經毒素
PL17201198T PL3326644T3 (pl) 2012-10-31 2013-10-31 Rekombinowane neurotoksyny Clostridium botulinum
HUE13811605A HUE036764T2 (hu) 2012-10-31 2013-10-31 Rekombináns Clostridium botulinum neurotoxinok
KR1020157010099A KR102188539B1 (ko) 2012-10-31 2013-10-31 재조합 클로스트리디움 보툴리눔 신경독
EP13811605.8A EP2914282B1 (en) 2012-10-31 2013-10-31 Recombinant clostridium botulinum neurotoxins
EP17201198.3A EP3326644B1 (en) 2012-10-31 2013-10-31 Recombinant clostridium botulinum neurotoxins
NO13811605A NO2914282T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2012-10-31 2013-10-31
TW108125708A TW202012622A (zh) 2012-10-31 2013-10-31 重組肉毒桿菌（Ｃｌｏｓｔｒｉｄｉｕｍ ｂｏｔｕｌｉｎｕｍ）神經毒素
PCT/GB2013/052845 WO2014068317A1 (en) 2012-10-31 2013-10-31 Recombinant clostridium botulinum neurotoxins
UAA201502159A UA118837C2 (uk) 2012-10-31 2013-10-31 Рекомбінантний нейротоксин clostridium botulinum
DK17201198.3T DK3326644T3 (da) 2012-10-31 2013-10-31 Rekombinante clostridium botulinum-neurotoksiner
AU2013340610A AU2013340610B2 (en) 2012-10-31 2013-10-31 Recombinant clostridium botulinum neurotoxins
TW102139558A TWI626307B (zh) 2012-10-31 2013-10-31 重組肉毒桿菌（Ｃｌｏｓｔｒｉｄｉｕｍ ｂｏｔｕｌｉｎｕｍ）神經毒素
EA201590794A EA201590794A8 (ru) 2012-10-31 2013-10-31 Рекомбинантные нейротоксины clostridium botulinum
KR1020207026658A KR102264478B1 (ko) 2012-10-31 2013-10-31 재조합 클로스트리디움 보툴리눔 신경독
SG11201502372SA SG11201502372SA (en) 2012-10-31 2013-10-31 Recombinant clostridium botulinum neurotoxins
PT138116058T PT2914282T (pt) 2012-10-31 2013-10-31 Neurotoxinas recombinantes de clostridium botulinum
CN201380047542.8A CN104755098A (zh) 2012-10-31 2013-10-31 重组的肉毒梭菌神经毒素
PL13811605T PL2914282T3 (pl) 2012-10-31 2013-10-31 Rekombinowane neurotoksyny Clostridium botulinum
NZ705575A NZ705575A (en) 2012-10-31 2013-10-31 Recombinant clostridium botulinum neurotoxins
ARP130103981A AR093309A1 (es) 2012-10-31 2013-10-31 Neurotoxinas recombinantes de clostridium botulinum
SG10201701140WA SG10201701140WA (en) 2012-10-31 2013-10-31 Recombinant clostridium botulinum neurotoxins
HUE17201198A HUE048802T2 (hu) 2012-10-31 2013-10-31 Rekombináns Clostridium botulinum neurotoxinok
CA2885519A CA2885519A1 (en) 2012-10-31 2013-10-31 Recombinant clostridium botulinum neurotoxins
ES13811605.8T ES2662402T3 (es) 2012-10-31 2013-10-31 Neurotoxinas recombinantes de Clostridium botulinum
JP2015540207A JP2015534814A (ja) 2012-10-31 2013-10-31 組換えクロストリジウムボツリヌス神経毒
ES17201198T ES2788199T3 (es) 2012-10-31 2013-10-31 Neurotoxinas recombinantes de Clostridium botulinum
CN201910795176.3A CN110499321A (zh) 2012-10-31 2013-10-31 重组的肉毒梭菌神经毒素
HK15109067.2A HK1208359B (en) 2012-10-31 2013-10-31 Recombinant clostridium botulinum neurotoxins
PT172011983T PT3326644T (pt) 2012-10-31 2013-10-31 Neurotoxinas recombinantes de clostridium botulinum
MX2015005156A MX367080B (es) 2012-10-31 2013-10-31 Neurotoxinas recombinantes de clostridium botulinum.
IN436MUN2015 IN2015MN00436A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2012-10-31 2013-10-31
ZA2015/01449A ZA201501449B (en) 2012-10-31 2015-03-03 Recombinant clostridium botulinum neurotoxins
IL237623A IL237623B (en) 2012-10-31 2015-03-08 Clostridium botulinum recombinant neurotoxins
MX2019009222A MX2019009222A (es) 2012-10-31 2015-04-23 Neurotoxinas recombinantes de clostridium botulinum.
AU2018203556A AU2018203556B2 (en) 2012-10-31 2018-05-21 Recombinant clostridium botulinum neurotoxins
JP2018230980A JP2019068823A (ja) 2012-10-31 2018-12-10 組換えクロストリジウムボツリヌス神経毒
ARP190103867A AR117738A2 (es) 2012-10-31 2019-12-26 Neurotoxinas recombinantes de clostridium botulinum
JP2020017612A JP2020078321A (ja) 2012-10-31 2020-02-05 組換えクロストリジウムボツリヌス神経毒
AU2020244481A AU2020244481A1 (en) 2012-10-31 2020-09-30 Recombinant clostridium botulinum neurotoxins

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201219602A GB201219602D0 (en) 2012-10-31 2012-10-31 Recombinant clostridium botulinum neurotoxins

Publications (1)

Publication Number Publication Date
GB201219602D0 true GB201219602D0 (en) 2012-12-12

Family

ID=47358958

Family Applications (1)

Application Number Title Priority Date Filing Date
GB201219602A Ceased GB201219602D0 (en) 2012-10-31 2012-10-31 Recombinant clostridium botulinum neurotoxins

Country Status (26)

Country Link
US (1) US10030238B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (3) EP3326644B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JP2019068823A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (2) KR102264478B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (2) CN104755098A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (2) AR093309A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (3) AU2013340610B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112015005384A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2885519A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (2) DK2914282T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA201590794A8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (2) ES2662402T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB201219602D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (2) HUE036764T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL237623B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2015MN00436A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (2) MX367080B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO2914282T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ705575A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (2) PL3326644T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (2) PT3326644T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (2) SG11201502372SA (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (3) TWI673361B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA118837C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2014068317A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA201501449B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201219602D0 (en) * 2012-10-31 2012-12-12 Syntaxin Ltd Recombinant clostridium botulinum neurotoxins
PL3274364T3 (pl) * 2015-03-26 2022-01-10 President And Fellows Of Harvard College Neurotoksyna botulinowa uzyskana technikami inżynierii
WO2017063743A1 (en) 2015-10-14 2017-04-20 Merz Pharma Gmbh & Co. Kgaa Improvements to ultrasound-based therapy of photoaged tissue
AU2017227978B2 (en) 2016-03-02 2022-03-10 Merz Pharma Gmbh & Co. Kgaa Composition comprising botulinum toxin
EP3263710A1 (en) * 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
US11117935B2 (en) 2016-08-24 2021-09-14 President And Fellows Of Harvard College Engineered botulinum neurotoxin
KR102635959B1 (ko) 2016-09-13 2024-02-14 알레간 인코포레이티드 안정화된 비단백질 클로스트리듐 독소 조성물
US11952601B2 (en) 2017-06-20 2024-04-09 Merz Pharma Gmbh & Co. Kgaa Recombinant botulinum toxin with increased duration of effect
US11155802B2 (en) 2017-07-06 2021-10-26 Merz Pharma Gmbh & Co. Kgaa Recombinant botulinum neurotoxins with increased duration of effect
EP3694489A4 (en) 2017-10-11 2021-06-30 Illustris Pharmaceuticals, Inc. Methods and compositions for topical delivery
AU2019211190B2 (en) * 2018-01-29 2021-07-08 Ipsen Biopharm Limited Non-neuronal SNARE-cleaving botulinum neurotoxins
US11707510B2 (en) * 2018-02-16 2023-07-25 Preclinics Discovery Gmbh Nucleic acid-based botulinum neurotoxin for therapeutic use
GB201815844D0 (en) * 2018-09-28 2018-11-14 Ipsen Biopharm Ltd Therapeutic & comestic uses of botulinum neurotoxin serotype e
GB202011055D0 (en) 2020-07-17 2020-09-02 Ipsen Bioinnovation Ltd Treatment of post-operative pain
GB202015618D0 (en) * 2020-10-01 2020-11-18 Ipsen Biopharm Ltd Method for producing beta-trypsin
CN115819526A (zh) * 2022-12-02 2023-03-21 海雅美生物技术(珠海)有限公司 一种重组肉毒杆菌神经毒素及其制备方法和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
NZ308772A (en) * 1995-05-17 1999-04-29 Du Pont Recombinant baculovirus insecticides
EP1119626B1 (en) 1998-07-10 2008-01-02 U.S. Army Medical Research Institute of Infectious Diseases Botulinum neurotoxin vaccine
EP2264052A3 (en) 1999-08-25 2011-04-20 Allergan, Inc. Activatable recombinant neurotoxins
US7374896B2 (en) 2001-08-28 2008-05-20 Allergan, Inc. GFP-SNAP25 fluorescence release assay for botulinum neurotoxin protease activity
US20110111483A1 (en) * 2004-06-30 2011-05-12 Allergan, Inc. Optimizing Expression of Active Botulinum Toxin Type E
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
WO2006011966A1 (en) * 2004-06-30 2006-02-02 Allergan, Inc. Optimizing expression of active botulinum toxin type e
GB2416122A (en) * 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
DE102004043009A1 (de) * 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
DE102005002978B4 (de) 2005-01-21 2013-04-25 Merz Pharma Gmbh & Co. Kgaa Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form
EP1853623B1 (en) * 2005-03-03 2013-05-08 Allergan, Inc. Animal product free system and process for purifying a botulinum toxin
EP1926744B2 (en) * 2005-09-19 2018-10-24 Allergan, Inc. Clostridial toxin activatable clostridial toxins
US20070218084A1 (en) * 2005-12-30 2007-09-20 Fondazione Pierfranco E Luisa Mariani- Onlus Method for the Mapping of the Epileptogenic Focus in the Pre-Surgical Evaluation of Patients with Intractable Epilepsy
EP2038299A2 (en) * 2006-07-11 2009-03-25 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
US8486422B2 (en) * 2007-07-26 2013-07-16 Allergan, Inc. Methods of activating clostridial toxins
JP2012512162A (ja) 2008-12-10 2012-05-31 アラーガン、インコーポレイテッド クロストリジウム毒素医薬組成物
GB0903006D0 (en) * 2009-02-23 2009-04-08 Syntaxin Ltd Modified non-cytotoxic proteases
AU2010236613B2 (en) * 2009-04-14 2016-07-07 Mcw Research Foundation, Inc. Engineered botulinum neurotoxin
RU2012129557A (ru) * 2009-12-16 2014-01-27 Аллерган, Инк. МОДИФИЦИРОВАННЫЕ ТОКСИНЫ Clostridial, СОДЕРЖАЩИЕ ИНТЕГРИРОВАННЫЙ САЙТ-СВЯЗЫВАЮЩИЙ ДОМЕН ПРОТЕАЗНОГО РАСЩЕПЛЕНИЯ
WO2012112434A1 (en) 2011-02-14 2012-08-23 Allergan, Inc. Inhibiting aberrant blood vessel formation using retargeted endopeptidases
GB201219602D0 (en) * 2012-10-31 2012-12-12 Syntaxin Ltd Recombinant clostridium botulinum neurotoxins
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
US11117935B2 (en) * 2016-08-24 2021-09-14 President And Fellows Of Harvard College Engineered botulinum neurotoxin

Also Published As

Publication number Publication date
EP3673914A1 (en) 2020-07-01
NO2914282T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-05-19
KR20200110470A (ko) 2020-09-23
WO2014068317A1 (en) 2014-05-08
ES2662402T3 (es) 2018-04-06
HUE036764T2 (hu) 2018-07-30
SG11201502372SA (en) 2015-05-28
UA118837C2 (uk) 2019-03-25
PT2914282T (pt) 2018-03-13
US20150247139A1 (en) 2015-09-03
AU2018203556A1 (en) 2018-06-07
US10030238B2 (en) 2018-07-24
MX2015005156A (es) 2015-09-23
PT3326644T (pt) 2020-05-29
CA2885519A1 (en) 2014-05-08
AU2013340610B2 (en) 2018-02-22
NZ705575A (en) 2019-08-30
CN104755098A (zh) 2015-07-01
IL237623A0 (en) 2015-04-30
MX2019009222A (es) 2019-11-21
DK3326644T3 (da) 2020-05-11
KR102188539B1 (ko) 2020-12-09
TWI673361B (zh) 2019-10-01
JP2019068823A (ja) 2019-05-09
ZA201501449B (en) 2016-08-31
MX367080B (es) 2019-08-05
KR20150094590A (ko) 2015-08-19
ES2788199T3 (es) 2020-10-20
HK1208359A1 (en) 2016-03-04
AU2013340610A1 (en) 2015-03-19
DK2914282T3 (en) 2018-02-26
EP3326644B1 (en) 2020-03-04
EP3326644A1 (en) 2018-05-30
PL3326644T3 (pl) 2020-08-24
JP2020078321A (ja) 2020-05-28
PL2914282T3 (pl) 2018-07-31
IL237623B (en) 2019-05-30
TWI626307B (zh) 2018-06-11
AR117738A2 (es) 2021-08-25
AR093309A1 (es) 2015-05-27
EA201590794A8 (ru) 2016-01-29
SG10201701140WA (en) 2017-04-27
KR102264478B1 (ko) 2021-06-15
CN110499321A (zh) 2019-11-26
TW201825680A (zh) 2018-07-16
TW202012622A (zh) 2020-04-01
TW201435084A (zh) 2014-09-16
BR112015005384A2 (pt) 2017-08-08
EP3673914B1 (en) 2021-10-27
EP2914282A1 (en) 2015-09-09
IN2015MN00436A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-09-04
AU2018203556B2 (en) 2020-08-20
HUE048802T2 (hu) 2020-08-28
AU2020244481A1 (en) 2020-10-29
EA201590794A1 (ru) 2015-08-31
EP2914282B1 (en) 2017-12-20

Similar Documents

Publication Publication Date Title
IL237623B (en) Clostridium botulinum recombinant neurotoxins
ZA201408757B (en) Engineered botulinum neurotoxin
DK3584317T3 (en) Clostridium histolyticum enzym
EP2807186A4 (en) DIFFICULT CLOSTRIDIUM VACCINES COMPRISING RECOMBINANT TOXINS
SG11201607400VA (en) Manufacture of recombinant clostridium botulinum neurotoxins
IL237132B (en) Variant of the fc region specific to fcгriib
HUE050037T2 (hu) Liofilizált botulinum toxin készítmény
FR2988733B1 (fr) Microorganisme recombinant
EP2925362A4 (en) ANTIBODIES DIRECTED AGAINST CLOSTRIDIUM DIFFICILE
IL237172A0 (en) פוליפפטידים של clostridium difficile כתרכיבים
SG10201507721SA (en) CHO-GMT Recombinant Protein Expression
HK40023045A (en) Solid compositions comprising recombinant clostridium botulinum neurotoxins
HK40104019A (en) Manufacture of recombinant clostridium botulinum neurotoxins
HK40102067A (en) Clostridium histolyticum enzyme
GB201215440D0 (en) Improved handover control
GB201210286D0 (en) Recombinant polypeptide
SG11201504096RA (en) Recombinant protein

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)